[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100513760":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":43,"responsibleParty":65,"collaborators":19,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":19,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":19,"enrollmentInfo":76,"targetDuration":19,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":87,"overallStatus":46,"whyStopped":19,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"University Hospital, Basel, Switzerland","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Wearing a smartwatch and glucose measuring device","EXPERIMENTAL","The intervention will be wearing a smart watch as well as continuous glucose monitoring with direct feedback via an application. Participants will wear these devices for 3 months.",[13,14],"Device: Fitbit Inspire 2","Device: Abbott Freestyle Libre 3",{"label":16,"type":17,"description":18,"interventionNames":19},"Standard care","NO_INTERVENTION","The control group will be given the standard recommendations that all patients completing cardiac rehabilitation receive.",null,[21,26],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":19},"DEVICE","Fitbit Inspire 2","A smartwatch (Fitbit Inspire 2) with its respective app will be worn by the patients in the intervention group for 3 months.",[9],{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":19},"Abbott Freestyle Libre 3","A continuous glucose measuring device (Abbott Freestyle Libre 3) with its respective app will be worn by the patients in the intervention group for 3 months.",[9],[31],{"name":32,"affiliation":5,"role":33},"Jan Gerrit van der Stouwe, Dr. med.","PRINCIPAL_INVESTIGATOR",[35,39],{"name":32,"role":36,"phone":37,"phoneExt":19,"email":38},"CONTACT","+41 61 265 44 44","jangerrit.vanderstouwe@usb.ch",{"name":40,"role":36,"phone":41,"phoneExt":19,"email":42},"Patrick Badertscher, Dr. med.","+41 61 265 52 14","patrick.badertscher@usb.ch",[44],{"facility":45,"status":46,"city":47,"state":19,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"University Hospital Basel","RECRUITING","Basel","4031","Switzerland","CH",{"type":52,"coordinates":53},"Point",[54,55],7.57327,47.55839,{"lat":55,"lon":54},[58,59,60,61,63],{"name":32,"role":36,"phone":37,"phoneExt":19,"email":38},{"name":40,"role":36,"phone":41,"phoneExt":19,"email":42},{"name":32,"role":33,"phone":19,"phoneExt":19,"email":19},{"name":40,"role":62,"phone":19,"phoneExt":19,"email":19},"SUB_INVESTIGATOR",{"name":64,"role":62,"phone":19,"phoneExt":19,"email":19},"Otmar Pfister, Prof. Dr. med.",{"type":66,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100513760","effect-of-monitoring-continuous-glucose-levels-and-physical-activity-via-wearables-on-cardiovascular-risk-factors-100513760",false,"NCT05969665","Effect of Monitoring Continuous Glucose Levels and Physical Activity Via Wearables on Cardiovascular Risk Factors","Effect of Monitoring Continuous Glucose Levels and Physical Activity Via Wearables on Cardiovascular Risk Factors After Cardiac Rehabilitation - A Randomised Controlled Trial: MITIGATE-RF","Inclusion Criteria:\n\n* Informed Consent signed by the subject\n* Completed outpatient cardiac rehabilitation\n* Diagnosis of coronary heart disease\n* Access to a smartphone for the duration of the study\n* 18 years or older on the date of consent\n\nExclusion Criteria:\n\n* Diseases which limit physical activity including angina with incomplete revascularisation, arrhythmogenic cardiomyopathy, stroke with residual disease, and major orthopaedic disorders\n* Known or suspected non-compliance\n* Inability to follow the procedures of the investigation, e.g., due to language problems, psychological disorders, dementia, etc. of the subject\n* Diabetic patients receiving insulin therapy\n* Lack of proficiency with smart phone\u002Fwatch\n* Current participation in any other clinical trial, which may confound the results of this trial.\n* NYHA (New York Heart Association) class III or IV congestive heart failure\n* Pregnancy","ALL","18 Years",{"count":77,"type":78},100,"ESTIMATED","INTERVENTIONAL",[81],"NA","The study aims to assess the effect of smart watches and continuous glucose measuring devices on cardiovascular risk factors.",[84,85,86],"Coronary Heart Disease","Physical Activity","Cardiovascular Risk Factors",[88,89,90,91,92,93],"blood pressure","lipids","glucose level","smoking","weight","diet","2024-08-13",{"date":96,"type":97},"2024-08-14","ACTUAL",{"date":99,"type":97},"2024-02-07",{"date":101,"type":78},"2025-08",{"name":5,"class":6},1]